Anupam Rasayan India Limited, one of India’s leading custom synthesis and specialty chemical companies, announced its financial results for the quarter and year ended March 31, 2026, delivering a strong operational and financial performance during FY26.
The company reported Total Revenue of Rs 23,836 Mn for FY26, compared to Rs 14,485 Mn in FY25, registering an impressive year-on-year growth of 65%. The robust performance was supported by higher product commercialization, increasing customer additions, and stronger contributions across key business verticals.
Strong Business Momentum Drives Growth
Anand Desai, Managing Director of Anupam Rasayan India Limited, said that FY26 marked a landmark year for the company as it continued to strengthen its position as a globally integrated specialty chemicals and CDMO player.
He highlighted that the company achieved its highest-ever annual sales and operating cash flow during the year, reflecting strong business momentum, operational efficiency, and healthy cash generation. The growth was largely driven by the commercialization of new products, onboarding of multinational customers, and expanding engagements across diversified business segments.
Focus on Complex Chemistries Strengthens Market Position
The company continued to deepen its presence in niche and complex chemistry segments, where high technical expertise and lengthy qualification cycles create strong entry barriers and sustainable long-term growth opportunities. This strategic focus has enabled the company to enhance its competitiveness while strengthening relationships with global innovator customers.
Jayhawk Acquisition Expands Global CDMO Footprint
One of the major strategic milestones during FY26 was the successful acquisition of Jayhawk Fine Chemicals in the United States.
The acquired business delivered a strong proforma revenue of $95 million, reinforcing the strategic importance of the transaction. The acquisition significantly enhances Anupam Rasayan’s global manufacturing footprint, advanced chemistry capabilities, and integrated CDMO platform. In addition, the acquisition improves the company’s access to regulated markets and innovator customers across North America, thereby strengthening its international presence.
Definitive Agreement Signed to Acquire Bliss GVS Pharma
Further strengthening its pharmaceutical value chain, Anupam Rasayan India Limited has signed a definitive agreement to acquire Bliss GVS Pharma Limited. As per the press release, the proposed acquisition is expected to create meaningful synergies across CDMO capabilities, product portfolio expansion, and customer relationships. It will also support the company’s long-term strategy of expanding its pharmaceutical and healthcare-focused business segments.
Outlook Remains Strong
The company remains optimistic about its future growth trajectory. Increasing contributions from the Performance Materials and Pharma segments, a strong product pipeline, and growing global customer engagements are expected to support the next phase of expansion. With strategic acquisitions, operational excellence, and a continued focus on innovation-led growth, Anupam Rasayan India Limited is well-positioned to strengthen its leadership in the specialty chemicals and CDMO space globally.
